Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition.
Brumpton BM, Fritsche LG, Zheng J, Nielsen JB, Mannila M, Surakka I, Rasheed H, Vie GÅ, Graham SE, Gabrielsen ME, Laugsand LE, Aukrust P, Vatten LJ, Damås JK, Ueland T, Janszky I, Zwart JA, Van't Hooft FM, Seidah NG, Hveem K, Willer C, Smith GD, Åsvold BO; INVENT Consortium.
Brumpton BM, et al. Among authors: asvold bo.
Circ Genom Precis Med. 2019 Jan;12(1):e002335. doi: 10.1161/CIRCGEN.118.002335.
Circ Genom Precis Med. 2019.
PMID: 30645169
Free PMC article.
No abstract available.